Samjin Pharmaceutical Co., Ltd.
June 16, 2025
Company Presentation
Immunology
Samjin Pharmaceutical Co., Ltd., a leading pharmaceutical company in Korea established in 1968, is dedicated to pioneering advancements in therapeutic innovation. Our portfolio features renowned products such as Platless® (antiarteriosclerotic agent), Neuracetam® (Nootropics), and Geworin® (NSAIDs), which have contributed significantly to our growth and success.
At Samjin, we focus on developing innovative treatments for diseases with high unmet medical needs, particularly those that are difficult to treat and pose significant challenges to today’s society. Our research focuses on conditions such as various cancers, immune disorders, and obesity.
We maintain a dynamic and diverse R&D pipeline, utilizing multiple modalities, including small molecules, ADCs, and TPDs. We actively collaborate with over 20 research institutions, and foster open innovation through strategic partnerships with domestic and global bio/pharmaceutical companies to drive medical breakthroughs.
Company HQ City:
Seoul
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
1968
Lead Product in Development:
SJN314 (MRGPRX2 antagonist)
CEO
Yong Joo Choi
Year Founded
1968
Development Phase of Lead Product
Pre-Clinical
Exchange
17,500.00 ₩ (Feb 6)
Ticker
005500.KS (KOSPI)
When you expect your next catalyst update?
Phase 1
What is your next catalyst (value inflection) update?
Dec., 2025
Website
https://www.samjinpharm.co.kr/front/en/main/index.asp
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}